Torrent Pharmaceuticals is currently trading at Rs. 1944.25, up by 45.90 points or 2.42% from its previous closing of Rs. 1898.35 on the BSE.The scrip opened at Rs. 1908.95 and has touched a high and low of Rs. 1964.50 and Rs. 1904.10 respectively. So far 1956 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.50 on 16-Jan-2020 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1964.50 and Rs. 1870.05 respectively. The current market cap of the company is Rs. 32277.41 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 20.79% and 7.96% respectively.Torrent Pharmaceuticals planning for raising funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. The Board of Directors of the Company at its meeting to be held on January 27, 2020 to consider the same.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1748.45, up by 67.75 points or 4.03% from its previous closing of Rs. 1680.70 on the BSE.The scrip opened at Rs. 1685.05 and has touched a high and low of Rs. 1753.80 and Rs. 1685.05 respectively. So far 20844 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1753.80 and Rs. 1640.90 respectively. The current market cap of the company is Rs. 29548.92 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 20.79% and 7.96% respectively.Torrent Pharmaceuticals has reported a rise of 18.41% in its net profit at Rs 328 crore for the quarter ended September 30, 2019 as compared to Rs 277 crore for the same quarter in the previous year. Total income of the company increased by 9.24% at Rs 1,726 crore for Q2FY20 as compared Rs 1580 crore for the corresponding quarter previous year. On the consolidated basis, the company has reported a rise of 36.31% in its net profit at Rs 244 crore for the quarter under review as compared to Rs 179 crore for the same quarter in the previous year. Total income of the company increased by 7.09% at Rs 2,039 crore for Q2FY20 as compared Rs 1,904 crore for the corresponding quarter previous year.

Torrent Pharmaceuticals is currently trading at Rs. 1629.60, down by 36.55 points or 2.19% from its previous closing of Rs. 1666.15 on the BSE.The scrip opened at Rs. 1580.00 and has touched a high and low of Rs. 1648.00 and Rs. 1554.65 respectively. So far 44807 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1,964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1670.35 and Rs. 1554.65 respectively. The current market cap of the company is Rs. 27513.34 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.Torrent Pharmaceuticals has received a warning letter from the US Food and Drug Administration (USFDA) for its Indrad facility in Gujarat. This action by the USFDA follows earlier intimation received from the regulator in August 2019, wherein the agency had classified its inspection as ‘Official Action Indicated’ (OAI). The company is committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1709.10, up by 13.85 points or 0.82% from its previous closing of Rs. 1695.25 on the BSE.The scrip opened at Rs. 1689.15 and has touched a high and low of Rs. 1715.15 and Rs. 1685.55 respectively. So far 2293 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1771.30 and Rs. 1673.45 respectively. The current market cap of the company is Rs. 28782.40 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.Torrent Pharmaceuticals has fully redeemed and repaid Commercial Paper (CP) of Rs 100 crore on September 23, 2019. The instrument was issued on May 17, 2019. Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1719.20, up by 4.15 points or 0.24% from its previous closing of Rs. 1715.05 on the BSE.The scrip opened at Rs. 1711.15 and has touched a high and low of Rs. 1726.70 and Rs. 1710.00 respectively. The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1771.30 and Rs. 1668.60 respectively. The current market cap of the company is Rs. 28934.69 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.Torrent Pharmaceuticals has fully redeemed and repaid Commercial Paper (CP) of Rs 100 crore on September 23, 2019. The instrument was issued on May 17, 2019. Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1712.30, up by 2.70 points or 0.16% from its previous closing of Rs. 1709.60 on the BSE.The scrip opened at Rs. 1707.60 and has touched a high and low of Rs. 1716.10 and Rs. 1703.90 respectively. So far 680 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.Last one week high and low of the scrip stood at Rs. 1744.45 and Rs. 1693.00 respectively. The current market cap of the company is Rs. 28831.47 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.Torrent Pharmaceuticals has issued Non-Convertible Debentures (NCDs) on Private Placement basis for an amount of Rs 300 crore on September 16, 2019. The tenure of the instrument is 1080 days and will mature on August 31, 2022.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1527.65, up by 71.80 points or 4.02% from its previous closing of Rs. 1468.60 on the BSE.The scrip opened at Rs. 1485.05 and has touched a high and low of Rs. 1558.45 and Rs. 1485.05 respectively. So far 54240 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1432.00 on 24-Jul-2018.Last one week high and low of the scrip stood at Rs. 1565.20 and Rs. 1453.00 respectively. The current market cap of the company is Rs. 26159.67 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.Torrent Pharmaceuticals has reported results for first quarter ended June 30, 2019.The company has reported a rise of 82.79% in its net profit at Rs 223 crore for the quarter under review as compared to Rs 122 crore for the same quarter in the previous year. Total income of the company increased by 9.96% at Rs 1,634 crore for Q1FY20 as compared Rs 1,486 crore for the corresponding quarter previous year.On the consolidated basis, the company has reported a rise of 32.52% in its net profit at Rs 216 crore for the quarter under review as compared to Rs 163 crore for the same quarter in the previous year. Total income of the company increased by 7.53% at Rs 2,042 crore for Q1FY20 as compared Rs 1,899 crore for the corresponding quarter previous year.

Torrent Pharmaceuticals is currently trading at Rs. 1559.20, up by 9.60 points or 0.62% from its previous closing of Rs. 1549.80 on the BSE.The scrip opened at Rs. 1549.80 and has touched a high and low of Rs. 1577.15 and Rs. 1539.50 respectively. So far 8855 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1407.45 on 23-Jul-2018.Last one week high and low of the scrip stood at Rs. 1577.15 and Rs. 1500.00 respectively. The current market cap of the company is Rs. 26356.80 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 19.14% and 9.61% respectively.Torrent Pharmaceuticals (Torrent) and Glenmark Pharmaceuticals (Glenmark) have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark will receive license fees and royalties for the non-exclusive sub-license rights from Torrent. Glenmark will manufacture and supply Remogliflozin, while Torrent will market the drug under its own trademark `Zucator` in India. Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1547.35, up by 34.80 points or 2.30% from its previous closing of Rs. 1511.45 on the BSE.The scrip opened at Rs. 1507.15 and has touched a high and low of Rs. 1552.45 and Rs. 1504.25 respectively. So far 5510 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1385.00 on 28-Jun-2018.Last one week high and low of the scrip stood at Rs. 1552.45 and Rs. 1479.35 respectively. The current market cap of the company is Rs. 26225.66 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 19.14% and 9.61% respectively.Torrent Pharmaceuticals has redeemed the Secured Redeemable Non-Convertible Debentures (NCDs) of Rs 83 crore. The company has repaid the same on June 24, 2019.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1581.40, down by 74.30 points or 4.49% from its previous closing of Rs. 1655.70 on the BSE.The scrip opened at Rs. 1634.90 and has touched a high and low of Rs. 1634.90 and Rs. 1525.20 respectively. So far 56338 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1282.00 on 25-May-2018.Last one week high and low of the scrip stood at Rs. 1681.60 and Rs. 1525.20 respectively. The current market cap of the company is Rs. 27037.02 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 19.14% and 9.61% respectively.Torrent Pharmaceuticals has reported a fall of 25.45% in its net profit at Rs 164 crore for the quarter ended March 31, 2019 as compared to Rs 220 crore for the same quarter in the previous year. However, total income of the company increased by 14.53% at Rs 1,584 crore for quarter under review as compared to Rs 1,383 crore for the quarter ended March 31, 2018.On consolidated basis, the company has reported a net loss of Rs 152 crore for the quarter ended March 31, 2019 against net profit of Rs 228 crore for the corresponding quarter in the FY18. However, total consolidated income of the company rose by 7.03% at Rs 1,873 crore for quarter under review as compared to Rs 1,750 crore for the same quarter ended previous year.For the year ended March 31, 2019, the company has posted a rise of 54.56% in its net profit at Rs 745 crore as compared to Rs 482 crore for the previous year. Total income of company increased 34.27% at Rs 6,144 crore for year under review as compared to Rs 4,576 crore for year ended March 31, 2018.For the year ended March 31, 2019, on the consolidated basis, the company has posted fall of 35.69% in its net profit at Rs 436 crore as compared to Rs 678 crore for the previous year. However, total income of company increased by 23.70% at Rs 7,730 crore for year under review as compared to Rs 6,249 crore for year ended March 31, 2018.

Torrent Pharmaceuticals is currently trading at Rs. 1666.70, up by 19.75 points or 1.20% from its previous closing of Rs. 1646.95 on the BSE.The scrip opened at Rs. 1681.60 and has touched a high and low of Rs. 1681.60 and Rs. 1649.05 respectively. So far 734 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1282.00 on 25-May-2018.Last one week high and low of the scrip stood at Rs. 1699.00 and Rs. 1612.10 respectively. The current market cap of the company is Rs. 28202.02 crore.The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 19.14% and 9.61% respectively.Torrent Pharmaceuticals has raised funds through issuance of Commercial Paper (CPs) for an amount of Rs 100 crore. The tenure of the instrument is 129 days and will mature on September 23, 2019. Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharmaceuticals is currently trading at Rs. 1750.95, up by 23.05 points or 1.33% from its previous closing of Rs. 1727.90 on the BSE.The scrip opened at Rs. 1723.25 and has touched a high and low of Rs. 1772.25 and Rs. 1723.00 respectively. So far 5738 shares were traded on the counter.The BSE group `A` stock of face value Rs. 5 has touched a 52 week high of Rs. 1964.00 on 29-Mar-2019 and a 52 week low of Rs. 1282.00 on 25-May-2018.Last one week high and low of the scrip stood at Rs. 1823.25 and Rs. 1720.00 respectively. The current market cap of the company is Rs. 29516.77 crore.The promoters holding in the company stood at 71.25%,while Institutions and Non-Institutions held 19.14% and 9.61% respectively.Torrent Pharmaceuticals has received certain observations from the US Food and Drug Administration (USFDA) for Indrad Plant which are procedural in nature and the company is confident of addressing them satisfactorily. The audit at Indrad Plant of the company was carried out by USFDA in the month of April, 2019.Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.